Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Save

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory disorders.

Mycophenolate in New-Onset SLE

Save

How aggressively do you treat newly diagnosed new-onset systemic lupus erythematosus (SLE), or should you wait for organ involvement?

TREAT EARLIER - Methotrexate in Clinically Suspect Arthralgia Patients

Save

Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein antibody (ACPA)-negative people with clinically suspect arthralgia.

FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis

Save

ACR Recommends QOL Self-Management Strategies

Save

American College of Rheumatology (ACR) experts identified research suggesting that patient self-management is not a

Moving Forward on RA Prevention Trials

Save

Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess interventions that may alter disease development.

Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency

Save

Glucocorticoids are widely prescribed as anti-inflammatory and immunosuppressive agents. This results in at least 1% of the population using chronic glucocorticoid therapy being at risk for glucocorticoid-induced adrenal insufficiency. This risk is dependent on the dose, duration and potency of the glucocorticoid, route of administration, and individual susceptibility.

ACR Backs FDA Rule Change on Interchangeable Biosimilars

Save

The American College of Rheumatology submitted comments to the U.S. Food & Drug Administration supporting their recent proposal to update the approval process for biosimilars’ interchangeability status by repealing the requirement for switching studies while also encouraging the FDA to continue monitoring the downstream effects of this policy to ensure transparency for patients and prescribing providers.

Less Mortality with GLP-1 Agonists in Rheumatic Patients

Save

A recent article in PLOS ONE has shown that treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists (GLP-1-RAs) was associated with a significant lowering of risk of all-cause mortality and major adverse cardiovascular events in patients with immune-mediated inflammatory diseases and type 2 diabetes.

Anti-CD40 Therapy in Sjögren's Disease

Save

Sjögren's disease is a chronic autoimmune condition without a clear effective therapy - DMARD or biologic. The TWINSS study has demonstrated the safety and efficacy of iscalimab, a monoclonal antibody against CD40, in a phase 2 randomized clinical trial of active Sjögren's disease (SD).

Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients

Save

Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axial spondyloarthritis (axSpA).

Barriers to Treat-to-Target in Rheumatoid Arthritis

Save

A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation.